Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application
Authors:
Open Access
- 7 January 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 1520
Abstract
Atherosclerosis (AS) is the leading cause of stroke and death worldwide. Although many lipid-lowering or antiplatelet medicines have been used to prevent the devastating outcomes caused by AS, the serious side effects of these medicines cannot be ignored. Moreover, these medicines are aimed at preventing end-point events rather than addressing the formation and progression of the lesion. Rapamycin (sirolimus), a fermentation product derived from soil samples, has immunosuppressive and anti-proliferation effects. It is an inhibitor of mammalian targets of rapamycin, thereby stimulating autophagy pathways. Several lines of evidence have demonstrated that rapamycin possess multiple protective effects against AS through various molecular mechanisms. Moreover, it has been used successfully as an anti-proliferation agent to prevent in-stent restenosis or vascular graft stenosis in patients with coronary artery disease. A thorough understanding of the biomedical regulatory mechanism of rapamycin in AS might reveal pathways for retarding AS. This review summarizes the current knowledge of biomedical mechanisms by which rapamycin retards AS through action on various cells (endothelial cells, macrophages, vascular smooth muscle cells, and T-cells) in early and advanced AS and describes clinical and potential clinical applications of the agent.Keywords
This publication has 116 references indexed in Scilit:
- Macrophage Autophagy Plays a Protective Role in Advanced AtherosclerosisCell Metabolism, 2012
- Autophagy as a therapeutic target in cardiovascular diseaseJournal of Molecular and Cellular Cardiology, 2011
- Adiponectin Induces Vascular Smooth Muscle Cell Differentiation via Repression of Mammalian Target of Rapamycin Complex 1 and FoxO4Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Autophagy in immunity and inflammationNature, 2011
- Eaten alive: a history of macroautophagyNature Cell Biology, 2010
- Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levelsBritish Journal of Pharmacology, 2009
- Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptorBritish Journal of Pharmacology, 2009
- FGFR1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expressionBiochemical and Biophysical Research Communications, 2009
- Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECMAtherosclerosis, 2006
- Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgeryJACC, 2004